Dual GLP-1/SGLT2 Therapy Before Transplant May Improve Post-Transplant Metabolic Outcomes | Research

The takeaway

Pre-transplant concurrent GLP-1 RA + SGLT2i use was associated with improved post-transplant metabolic outcomes in solid organ transplant recipients, providing early evidence for dual metabolic preparation.

Metabolic preparation
Using both GLP-1 and SGLT2 drugs before transplant may prepare the body metabolically for better post-transplant outcomes

What the researchers found

Pre-transplant dual GLP-1 RA + SGLT2i therapy associated with improved post-transplant metabolic outcomes in solid organ transplant recipients.

Why it matters

Transplant recipients with obesity and diabetes have worse graft survival. Pre-transplant metabolic optimization could improve outcomes.

How the study worked

Retrospective evaluation of pre-transplant dual GLP-1 RA + SGLT2i use and post-transplant metabolic outcomes.

What this study cannot tell us

Limited evidence. Retrospective. Small sample implied. Cannot separate individual drug contributions.

How to read the evidence

Limited retrospective evidence. Important concept needing prospective validation.

When this study was published

Published in 2025.

The bigger picture

Pre-transplant metabolic optimization is a new paradigm — preparing the body's metabolism before the transplanted organ arrives.

Questions still open

Should dual metabolic therapy become standard pre-transplant protocol?
How long before transplant should dual therapy begin?
Does pre-transplant metabolic optimization improve graft survival?

Common questions

Should transplant patients take GLP-1 and SGLT2 drugs before surgery?

Early evidence suggests dual therapy may improve metabolic outcomes after transplant. This approach is gaining interest but needs larger studies to confirm.

Why does metabolism matter for transplants?

Poor metabolic health (obesity, diabetes) shortens transplant organ survival. Optimizing metabolism before surgery may give the new organ a better environment to function in.

Read the original research

Effectiveness of Pre-Transplant Dual GLP-1 Receptor Agonist and SGLT2 Inhibitor Therapy on All-Cause Mortality in Organ Transplantation Candidates with Obesity and Type 2 Diabetes: a Target-Trial Emulation.

Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(11), e18813

View on PubMed ↗Publisher’s paper ↗

Citation

Huang, Yu-Nan; Tsou, Min-Yu; Li, Pin-Hung; Chen, Jo-Ching; Liu, Yen-Liang; Meyerowitz-Katz, Gideon; Tsai, Tsung-Hsun; Su, Pen-Hua. (2026). Effectiveness of Pre-Transplant Dual GLP-1 Receptor Agonist and SGLT2 Inhibitor Therapy on All-Cause Mortality in Organ Transplantation Candidates with Obesity and Type 2 Diabetes: a Target-Trial Emulation.. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(11), e18813. https://doi.org/10.1002/advs.202518813